Bevacizumab With or Without Cyclophosphamide and Methotrexate: A Pilot Study in Women With Operable Breast Cancer
Anti-Angiogenesis Treatment After Preoperative Chemotherapy: A Pilot Study in Women With Operable Breast Cancer
The purpose of this research study is to study the effects (good and bad) of bevacizumab alone, bevacizumab with low-dose continuous chemotherapy (called metronomic chemotherapy), or bevacizumab with capecitabine, on you and your cancer. The goals of the study will be to:
- Examine the safety of these drugs
- See how easy or difficult it is to be treated with them
- Monitor for any signs of recurrent cancer
- Look at blood markers that might indicate how the treatment is working
研究概览
详细说明
This study is broken into 4 groups (A, B, C, and D). Enrollment closed to all groups in May 2008.
The first forty subjects (Group A) in this study were treated with Bevacizumab only, which is given through a vein over 1-2 hours every 3 weeks, for a total of approximately 12 months (17 cycles). Each cycle consists of 3 weeks.
The next forty subjects (Group B) were treated with Bevacizumab and metronomic CM chemotherapy. These subjects took cyclophosphamide (1 pill by mouth every day), methotrexate, (1 pill taken by mouth twice a day for the first two days of each week) and Bevacizumab (once every 3 weeks). The treatments with cyclophosphamide, methotrexate and Bevacizumab will continue for approximately 6 months (8 cycles). Then for the next 6 months, they received Bevacizumab treatments only. The total time on this study will be about 12 months (17 cycles).
The next forty subjects (Group C) were treated with Bevacizumab and Capecitabine chemotherapy. These subjects took Capecitabine pills twice a day for 14 days, then one week of rest, to complete a 21-day cycle. There will be a total of 6 cycles of Capecitabine, meaning 18 weeks of treatment with both Capecitabine and Bevacizumab. Then received Bevacizumab treatments only (11 cycles) to complete 12 months of therapy. Total duration of your treatment will be about 12 months or 17 cycles of therapy.
The last forty subjects (Group D) are being treated with Bevacizumab and Capecitabine chemotherapy on a different schedule. These subjects will take Capecitabine pills twice a day for 7 days, then one week of rest and repeat this for a total of 24 weeks (6 cycles). Each cycle will last for 4 weeks (28 days). There will be a total of 6 cycles of Capecitabine, meaning 24 weeks of treatment with both Capecitabine and Bevacizumab. Bevacizumab will be given every two weeks for a total of 24 weeks (6 cycles). Then they will receive Bevacizumab treatments only, every 3 weeks for additional 27 weeks (9 cycles) to complete 12 months of therapy. For the last 9 cycles of Bevacizumab therapy each cycle will consist of 3 weeks. Total duration of treatment will be about 12 months or 15 cycles of therapy.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
California
-
San Francisco、California、美国、94122
- University of California, San Francisco
-
-
Indiana
-
Indianapolis、Indiana、美国、46202
- Indiana University Cancer Center
-
-
Massachusetts
-
Boston、Massachusetts、美国、02115
- Dana-Farber Cancer Institute
-
Boston、Massachusetts、美国、02115
- Beth Israel Deaconess Medical Center
-
-
North Carolina
-
Durham、North Carolina、美国、27701
- University of North Carolina
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically or cytologically confirmed invasive breast cancer, preoperative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging
- Patients must have completed preoperative (neoadjuvant) chemotherapy with a standard chemotherapy regimen. No more chemotherapy should be planned.
- Patients must have completed definitive resection of primary tumor with adequate excision of gross disease.
- For patients receiving adjuvant radiation therapy, treatment must be completed prior to initiation of protocol therapy.
- Patients must have the presence of significant residual invasive disease on pathologic review following their preoperative chemotherapy.
- LVEF > institutional limits of normal after preoperative chemotherapy, as assessed by ECHO or nuclear medicine gated study, within 30 days prior to initiating protocol-based treatment.
- ECOG performance status 0-1
Exclusion Criteria:
- Inadequate organ function, as measured by laboratory assessment after preoperative chemotherapy and within 14 days of beginning protocol-based treatment
- Patients with metastatic disease are ineligible.
- Known HIV infection
- Patients may not be pregnant, expect to become pregnant, plan to conceive a child while on study, or breastfeeding
- Uncontrolled intercurrent illness
- Non-healing wounds or major surgical procedures (such as breast surgery) other than that for venous access device or diagnostic study are not permitted within 28 day prior to enrollment
- History of abdominal fistula, GI perforation, intra-abdominal abscess, or serious, non-healing wound, ulcer, or bone fracture within 6 months prior to initiating bevacizumab
- Patients with any history of arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular event (CVA), unstable angina, or myocardial infarction (MI) within the past 6 months. Patients with clinically significant peripheral arterial disease should also be excluded
- History of bleeding diathesis or coagulopathy
- History of grade 3 or 4 allergic reactions to compounds of similar chemical or biologic composition to cyclophosphamide (such as other alkylating agents) or methotrexate (such as other antimetabolites)
- Prior history of malignancy treated without curative intent, excluding nonmelanomatous skin cancer
- Patients with large or rapidly accumulating pleural or abdominal effusions
- Current use of anticoagulants is allowed as long as patients have been on a stable dose for more than two weeks with stable INR
- Chronic therapy with full dose aspirin (< 325 mg/day) or standard non-steroidal anti-inflammatory agents is allowed
- Patients may not receive other investigational agents while on study
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
---|---|
实验性的:Group A
Bevacizumab Alone
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
其他名称:
|
实验性的:Group B
Bevacizumab with cyclophosphamide and methotrexate
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
其他名称:
Once a day for 6 months
其他名称:
Twice daily for the first two days of every week for 6 months
其他名称:
|
实验性的:Group C
capecitabine, 14 days on/7 days off scheduling, and bevacizumab
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
其他名称:
Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks) Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
其他名称:
|
实验性的:Group D
capecitabine 7 days on/7 days off scheduling, and bevacizumab
|
Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
其他名称:
Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks) Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
---|---|
The Completion Rate of 1 Year of Bevacizumab Therapy for All Four Cohorts
大体时间:1 year
|
1 year
|
合作者和调查者
合作者
调查人员
- 首席研究员:Harold J Burstein, MD, PhD、Dana-Farber Cancer Institute
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- 05-055
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Bevacizumab的临床试验
-
Weill Medical College of Cornell University终止多形性胶质母细胞瘤 | 间变性星形细胞瘤 | 弥漫性脑桥脑胶质瘤 | 脑干胶质瘤 | 毛粘液样星形细胞瘤 | 脑干胶质瘤 | 脑纤维星形细胞瘤 | 混合性少突胶质细胞瘤-星形细胞瘤美国
-
Sixth Affiliated Hospital, Sun Yat-sen University招聘中
-
National Cancer Institute (NCI)NRG Oncology完全的恶性卵巢上皮性肿瘤 | 卵巢两性母细胞瘤 | 卵巢支持间质细胞瘤 | 卵巢性索肿瘤伴环状小管 | 卵巢类固醇细胞瘤 | 卵巢颗粒细胞瘤 | 卵巢性索间质瘤 | 混合或未分类细胞类型的卵巢性索间质瘤美国